Ganga Pharmaceuticals Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Ganga Pharmaceuticals Ltd is ₹ 12 as of 12 Feb 15:30 . The P/E Ratio of Ganga Pharmaceuticals Ltd changed from 113.9 on March 2022 to 63.6 on March 2025 . This represents a CAGR of -13.56% over 4 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Ganga Pharmaceuticals Ltd changed from ₹ 4.16 crore on March 2022 to ₹ 4.92 crore on March 2025 . This represents a CAGR of 4.28% over 4 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The revenue of Ganga Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The ebitda of Ganga Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The net profit of Ganga Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Ganga Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Limited was incorporated as a Public Limited Company in Aug.'94 and promoted by Brij Mohan Sharma.
The Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda). In Apr.'95, the company took over Ganga pharmaceuticals, a proprietary concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.'95.
In Jul.'96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra. The company which commenced exports in Jan.'96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Ganga Pharmaceuticals Ltd or Parmax Pharma Ltd?

Market cap of Ganga Pharmaceuticals Ltd is 7 Cr while Market cap of Parmax Pharma Ltd is 12 Cr

What are the key factors driving the stock performance of Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd?

The stock performance of Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd?

As of May 6, 2026, the Ganga Pharmaceuticals Ltd stock price is INR ₹12.0. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.49.

How do dividend payouts of Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Ganga Pharmaceuticals Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.